A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylate Administered with Ribavirin

Trial Profile

A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylate Administered with Ribavirin

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2012

At a glance

  • Drugs RG 7795 (Primary) ; Antivirals; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2011 Anadys Pharmaceuticals intends to start this trial in Q2 of 2011 and expects to receive 4 week viral load data for ANA 773 plus ribavirin in Q4 of 2011.
    • 08 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top